Longeveron
Longeveron

Longeveron

Biotechnology
WebsiteInvestor RelationsSEC
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD) and Aging-related Frailty.

$5.1M

Market Cap • 10/23/2026

2014

(12 years)

Founded

2021

(5 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

0,5

P/S

4,3

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

3,3

EPS

—

Market Cap

Market Cap

5,1M

EV

-4,4M

EV/Revenue

-3,7

EV/EBITDA

0,2

EV/EBIT

0,2

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-382,9%

Total Yield

-382,9%

Payout

0%

Retained Earnings

-143,1M

Profitability

Gross Margin

69,8%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

1018,1%

Capex/Revenue

13,5%

Capex/D&A

15,8%

Capex/OCF

-0,8%

SBC/OCF

—

% PPE

12,6%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

-21,2%

CAGR Op. Income 5Y

16,8%

CAGR Net Income 5Y

17,6%

CAGR EPS 5Y

-29,8%

CAGR OCF 5Y

24,8%

Leverage

N.D./EBITDA

0,4

Debt/Equity

0%

Current Ratio

2,6

Quick Ratio

2,4

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium